Summary
This 8-K/A filing from Edwards Lifesciences (EW) on February 7, 2018, serves as an amendment to a previous filing, primarily to provide revised financial information for the fourth quarter and full year ended December 31, 2017. The revision is due to an adjustment in the company's calculation of its tax on unremitted foreign earnings for the period. Investors should note that this revised financial data was initially announced in a press release on February 1, 2018. The core of this amendment is Exhibit 99.1, which contains the updated financial results. While the filing does not detail the specific financial performance figures in the text, it directs investors to the furnished exhibit for the precise revised numbers. The information provided is furnished and not deemed 'filed' under the Securities Exchange Act of 1934, meaning it doesn't carry the same legal implications for the company regarding liability for the accuracy of the information.
Key Highlights
- 1Edwards Lifesciences (EW) filed an 8-K/A to amend prior financial reporting.
- 2The amendment revises the company's computation of tax on unremitted foreign earnings for Q4 and full-year 2017.
- 3Revised financial information for the three and twelve months ended December 31, 2017, is provided as Exhibit 99.1.
- 4The original press release announcing these results was issued on February 1, 2018.
- 5The information furnished in this report is not deemed 'filed' for the purposes of Section 18 of the Exchange Act.
- 6This filing focuses on correcting a specific tax calculation impacting prior period results.